On 20 October 2025, Shandong Weigao Group Medical Polymer Company Limited (01066) announced a repurchase of 249,600 H shares on the Stock Exchange. The transaction accounted for approximately 0.0055% of its previously issued shares (excluding treasury shares). The highest repurchase price per share was HKD 5.61, and the lowest was HKD 5.60, resulting in a total payment of HKD 1,398,456.

After this repurchase, the company’s issued shares stand at 4,500,240,724 shares (excluding treasury shares), while the number of treasury shares increased to 22,091,600. The total issued share count remained at 4,522,332,324.

The repurchase was executed under a mandate dated 27 May 2025, which authorizes the company to repurchase up to 451,560,392 shares. A total of 15,443,200 shares, representing 3.42% of the company’s issued shares (excluding treasury shares) at the time of the mandate, have been repurchased to date. The moratorium period for any new issue of shares or sale or transfer of treasury shares extends through 19 November 2025.